With the XJO surging forward today it was expected that a rising tide would lift all boats, something is not right here. Very little support & low volume, it may pay SRX to communicate more often & broadly as investors require updates, perhaps their corporate affairs dept could publish a newsletter.
Yttrium-90 resin microspheres as an adjunct to sorafenib in patients with unresectable hepatocellula, page-4
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)